Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371004 · ClinicalTrials.gov registry record · Phase 1
DM-CHOC-PEN Plus Radiation for Brain Tumors
A Phase 1 study of Advanced Cancer, sponsored by DEKK-TEC.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT03371004: Completed Phase 1 study of Advanced Cancer, sponsored by DEKK-TEC.
NCT03371004 is a Phase 1 study of Advanced Cancer that has completed, run by DEKK-TEC. The registered enrollment target is 19 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03371004, a Phase 1 study of Advanced Cancer, has completed, sponsored by DEKK-TEC.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein) (1). DM-CHOC-PEN has completed Phase I/II trials in humans with primary and secondary tumors involving the brain with success. Complete remissions in both primary astrocytoma and metastatic lung and leukemia malignancies. This trial is open for adult subjects with advanced cancer - brain involvement is required.
Primary Outcome
Laboratory and imaging studies to verify responses
Conditions Studied
Interventions
- DRUG 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Study Locations (3)
Louisiana
- Tulane University Medical Center - New Orleans
- Tulane University Medical School - New Orleans
Michigan
- Detroit Clinical Research Centers - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
What the finished NCT03371004 record still lists
NCT03371004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which 4-Demethyl-4-cholesteryloxycarbonylpenclomedine is the first listed.
NCT03371004 reports a single indexed study location in Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT03371004 about?
NCT03371004 is a clinical study titled "DM-CHOC-PEN Plus Radiation for Brain Tumors". 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain ...
What is the current status of trial NCT03371004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-02-05. Estimated completion is 2022-10-01.
What conditions does trial NCT03371004 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT03371004?
The interventions under investigation include: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DRUG).
Who is sponsoring clinical trial NCT03371004?
This trial is sponsored by DEKK-TEC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371004 being conducted?
This trial has 3 study locations across Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03371004's enrollment target sits among peer trials
19 114th of 122 higher than 8 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI